Inoviq Ltd (ASX: IIQ) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Inoviq Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $54.20 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 140.78 million
Earnings per share -0.062
Dividend per share N/A
Year To Date Return 0.65%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Inoviq Ltd (ASX: IIQ)
    Latest News

    Three rockets heading to space
    Share Gainers

    3 ASX biotech shares rocketing 10% to 26% on BIG news!

    Investors are sending these three ASX biotech stocks flying higher on Thursday.

    Read more »

    Female scientist working in a laboratory.
    Healthcare Shares

    What's going on with the Inoviq (ASX:IIQ) share price today?

    The company is set to finish the week on a high note.

    Read more »

    A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
    Healthcare Shares

    Why has the BARD1 (ASX:BD1) share price vanished from the ASX boards?

    Where are BARD1's shares hiding?

    Read more »

    Vanadium Resources share price person riding rocket indicating share price increase
    Share Gainers

    BARD1 (ASX:BD1) share price ends stellar day up 41%

    BARD1 had a fantastic day...

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    BARD1 Life Sciences (ASX:BD1) share price leaps 16% on US patent news

    The company's shares are set to finish the week on a positive note.

    Read more »

    man jumping along increasing bar graph signifying jump in alumina share price
    Share Market News

    BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update

    The quest for BARD1's ELISA test takes another step forward.

    Read more »

    Healthcare Shares

    Here's why the BARD1 (ASX:BD1) share price is falling 7% today

    The market is responding poorly to BARD1's fourth-quarter activities

    Read more »

    share price dropping
    Share Fallers

    Why BARD1, Imugene, Northern Star, & Silver Lake shares are sinking

    It hasn't been a good day for these ASX shares...

    Read more »

    laboratory workers looking disappointed
    Capital Raising

    BARD1 (ASX:BD1) share price falls 6% on placement update

    The medical diagnostics company has secured the first part of its equity raise...

    Read more »

    A dollar sign embedded in ice, indicating a share price freeze or trading halt
    Share Market News

    Here's why the BARD1 (ASX:BD1) share price is frozen today

    All eyes are on BARD1 Life Sciences' halted shares.

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    Why the BARD1 (ASX:BD1) share price is surging 10% higher

    This healthcare share is on fire today...

    Read more »

    A businessman holds his glasses in concern, indicating uncertainly in the ASX share price
    Share Fallers

    Why the BARD1 (ASX:BD1) share price plummeted 9% today

    The BARD1 Life Sciences Ltd share price has sunk 9% despite announcing a positive update. We take a closer look…

    Read more »

    IIQ ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Inoviq Ltd

    INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. Its activities include research and development of non-invasive diagnostic tests for early detection of cancer, based on certain proprietary intellectual property. The company was founded on June 30, 1983 and is headquartered in Subiaco, Australia.

    IIQ Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    19 Jan 2026 $0.39 $-0.01 -2.56% 157,212 $0.39 $0.40 $0.38
    16 Jan 2026 $0.39 $0.01 2.60% 112,367 $0.39 $0.39 $0.38
    15 Jan 2026 $0.39 $0.01 2.63% 95,189 $0.38 $0.39 $0.38
    14 Jan 2026 $0.38 $-0.01 -2.60% 124,035 $0.39 $0.39 $0.38
    13 Jan 2026 $0.39 $-0.01 -2.53% 140,673 $0.40 $0.40 $0.38
    12 Jan 2026 $0.40 $-0.01 -2.47% 145,985 $0.41 $0.41 $0.40
    09 Jan 2026 $0.41 $0.01 2.50% 291,418 $0.40 $0.41 $0.40
    08 Jan 2026 $0.40 $0.02 5.19% 114,946 $0.39 $0.41 $0.39
    07 Jan 2026 $0.39 $-0.01 -2.53% 120,650 $0.40 $0.40 $0.38
    06 Jan 2026 $0.40 $0.00 0.00% 160,903 $0.40 $0.41 $0.39
    05 Jan 2026 $0.40 $-0.01 -2.50% 130,210 $0.40 $0.40 $0.39
    02 Jan 2026 $0.40 $0.01 2.58% 164,363 $0.39 $0.41 $0.39
    31 Dec 2025 $0.39 $0.02 5.48% 111,654 $0.38 $0.39 $0.38
    30 Dec 2025 $0.37 $-0.01 -2.67% 189,976 $0.39 $0.39 $0.37
    29 Dec 2025 $0.38 $0.02 5.67% 308,123 $0.37 $0.39 $0.37
    24 Dec 2025 $0.35 $0.00 0.00% 16,193 $0.35 $0.35 $0.35
    23 Dec 2025 $0.35 $0.00 0.00% 188,860 $0.35 $0.36 $0.35
    22 Dec 2025 $0.35 $0.01 2.99% 394,676 $0.34 $0.35 $0.34

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    05 Nov 2025 Philip (Phil) Powell Buy 85,714 $29,999
    Participation in share purchase plan.
    05 Nov 2025 Robert (Max) Johnston Buy 85,714 $29,999
    Participation in share purchase plan.
    10 Mar 2025 Philip (Phil) Powell Buy 50,000 $17,500
    On-market trade.
    10 Mar 2025 Robert (Max) Johnston Buy 37,839 $13,243
    On-market trade.
    07 Mar 2025 Robert (Max) Johnston Buy 162,161 $56,756
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Philip (Phil) John Powell Non-Executive Director Jun 2019
    Mr Powell has experience in investment banking, specializing in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. He is the Chair of the Company's Risk Committee.
    Mr Peter Lynton Gunzburg Non-Executive Director Oct 2025
    Mr Gunzburg brings over 40 years experience as a public company director, stockbroker, and investor. He previously served as Chairman of BARD1 Life Sciences Limited (now INOVIQ Ltd) from 2016 to 2020. Mr Gunzburg is currently Chairman of Metals X Limited (ASX: MLX) and a Non-Executive Director of London Stock Exchange listed First Tin Plc (LSE: 1SN). Mr Gunzburg has also previously been a director of Australian Stock Exchange Ltd, Eyres Reed Ltd, CIBC World Markets Australia Ltd and several other public companies.
    Mr Geoffrey A. Cumming Non-Executive Director Jul 2020
    Dr Cumming has held senior roles in the global healthcare and biotechnology sector for 20 years. He is a member of the INOVIQ Limited Risk Committee. He has not been a director of any listed companies in the last three years other than those listed above.
    Mr Robert (Max) Maxwell Johnston Non-Executive Director Jun 2019
    Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the medical, pharmaceutical and consumer healthcare company for 11 years. He has also held several industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Self Medication Industry (ASMI). He is a member of the Company's Risk Committees. He has not been a director of any listed companies in the last three years other than those listed above
    Ms Mary Harney Non-Executive Director Oct 2024
    Ms Harney is a Non-Executive Director and Chief Executive has experience of applied science research, in addition to experience in biopharmaceutical regulatory affairs and commercialization. She is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovative industries such as health, biotech and agriculture. She currently serves as Chair of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company. She was also previously a former Chair of Microbio Limited.
    Dr Leearne Hinch Chief Executive Officer Nov 2016
    -
    Mr Mark Edwards Chief Financial OfficerCompany Secretary Nov 2022
    -
    Leearne Hinch Chief Executive Officer
    -
    Mark Edwards Chief Financial OfficerCompany Secretary
    -
    DR GREGORY RICE CHIEF SCIENTIFIC OFFICER
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    The Trust Company Australia Limited <Mof A/C> 6,487,000 5.81%
    Dr Irmgard Irminger-Finger 3,150,000 2.82%
    Lawn Views Pty Ltd <Angela Williams Family A/C> 2,676,924 2.40%
    Lesamourai Pty Ltd 2,530,495 2.27%
    Moggs Creek Pty Ltd <Moggs Creek Super A/C> 2,389,747 2.14%
    Mr Peter William Rogers + Ms Alida Johanna Clark <R&C Super Fund A/C> 1,804,436 1.62%
    J P Morgan Nominees Australia Pty Limited 1,655,031 1.48%
    Supergun Pty Ltd <Bricklanding Super Fund A/C> 1,271,000 1.14%
    Trovex Pty Ltd 1,150,000 1.03%
    Mr Neil Donal Delroy <The Ndd Investment A/C> 1,135,086 1.02%
    Mr Nathan Ryan Wagner 1,010,562 0.91%
    Mr Adam Garrigan 1,000,000 0.90%
    Faraday Nominees Pty Limited <Bronte Investment A/C> 1,000,000 0.90%
    Palmers Plumbing & Hardware Pty Ltd 962,256 0.86%
    CITICORP Nominees Pty Limited 940,051 0.84%
    David Neate 902,257 0.81%
    S3 Consortium Pty Ltd 750,000 0.67%
    Jondol Pty Ltd <Jondol Estates S/F A/C> 711,289 0.64%
    Netwealth Investments Limited <Wrap Services A/C> 670,394 0.60%
    B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> 660,000 0.57%

    Profile

    since

    Note